Primary tabs
The list of publications is indicative and may not include all publications.
Use of cystic fibrosis inhaled medication before and after elexacaftor/tezacaftor/ivacaftor initiation.
Journal of Cystic Fibrosis.
(2023).
Availability and costs of medicines for the treatment of tuberculosis in Europe.
Clinical Microbiology and Infection. 29(1), 77 - 84.
(2023).
Tigecycline Pharmacokinetic and Pharmacodynamic Profile in Patients with Chronic Obstructive Pulmonary Disease Exacerbation.
Antibiotics. 12(2), 307.
(2023).
Evaluation of Pain Scales and Outcome in Critically Ill Patients of a Greek ICU..
J Pain Palliat Care Pharmacother. 37(1), 34-43.
(2023).
The war in Ukraine and potential consequences for the TB epidemic in Europe..
Int J Tuberc Lung Dis. 26(5), 470-471.
(2022).
Adherence to inhaled therapies over 4 years in people with cystic fibrosis..
Pediatr Pulmonol. 57(4), 956-964.
(2022).
Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study..
J Bras Pneumol. 48(2), e20220087.
(2022).
BALF and BLOOD NK- cells in different stages of pulmonary sarcoidosis..
Sarcoidosis Vasc Diffuse Lung Dis. 38(4), e2021039.
(2022).
Clinical, imaging and functional determinants of sarcoidosis phenotypes in a Greek population..
J Thorac Dis. 14(6), 1941-1949.
(2022).
Pulmonary medication adherence among children and adults with cystic fibrosis: Is there an association with disease severity?.
Pediatr Pulmonol. 57(12), 3017-3026.
(2022).
TB and COVID-19 co-infection: rationale and aims of a global study..
Int J Tuberc Lung Dis. 25(1), 78-80.
(2021).
Occupational Exposure to Zoonotic Tuberculosis Caused by Mycobacterium caprae, Northern Greece, 2019..
Emerg Infect Dis. 27(7), 1997-1999.
(2021).
Clinical standards for the assessment, management and rehabilitation of post-TB lung disease..
Int J Tuberc Lung Dis. 25(10), 797-813.
(2021).
Severe Pulmonary Disease Caused by Mycolicibacter kumamotonensis..
Emerg Infect Dis. 27(3), 962-964.
(2021).
18F-FDG PET/CT contribution to tuberculous vertebral osteomyelitis diagnosis: a case report..
Oxf Med Case Reports. 2020(9), omaa068.
(2020).
MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network.
International Journal of Infectious Diseases. 92, S15 - S25.
(2020).
Longitudinal Changes in Exercise Capacity among Adult Cystic Fibrosis Patients.
Advances in Respiratory Medicine. 88(5), 420 - 423.
(2020).
Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis PatientsABSTRACT.
Antimicrobial Agents and Chemotherapy. 63(7),
(2019).
Tuberculosis treatment outcome in Thessaloniki, Greece - a single center study..
Hippokratia. 23(4), 154-159.
(2019).
A rare pulmonary pathology complicated with an unusual condition.
Breathe. 15(2), 121 - 127.
(2019).
Moxifloxacin in Chronic Obstructive Pulmonary Disease: Pharmacokinetics and Penetration into Bronchial Secretions in Ward and Intensive Care Unit PatientsABSTRACT.
Antimicrobial Agents and Chemotherapy. 63(3),
(2019).
Genetic diversity of mycobacterium tuberculosis in northern Greece..
J Biol Regul Homeost Agents. 32(4), 931-936.
(2018).
Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
European Respiratory Journal. 49(5), 1700387.
(2017).
Miliary tuberculosis in a patient with tuberculous mycotic aneurysm of the abdominal aorta: Case report and review of the literature..
Respir Med Case Rep. 21, 30-35.
(2017).